ESTEVE’S RDI, AGAIN RATED ’EXCELLENT’ BY THE PROFARMA PLAN
The Profarma Plan (Plan for the Promotion of Scientific Research, Development and Technological Innovation in the Pharmaceutical Industry), a joint program of the Ministry of Industry, Energy and Tourism and of the Ministry of Health, Social Services and Equality, has again rated ESTEVEs RDI as 'excellent'
This rating acknowledges the companys commitment to innovation, with an important part of its workforce devoted to top-level research. Over the last year, ESTEVE has invested more than 81 million Euros in R&D.
ESTEVE appears in Group A of the Profarma Plan (2017-2020), which includes companies that conduct significant research activities and have their own center of production or basic or preclinical R&D.
The main purpose of the Profarma Plan is to increase the competitiveness of the pharmaceutical industry in Spain by modernizing the sector, strengthening the activities that provide the highest added value, and fostering research, development and innovation.
THE PROGRAM ’PLAN PROFARMA’ HAS ONCE AGAIN QUALIFIED ESTEVE’S R&D&I AS ’’EXCELLENT’’
Once again, ESTEVE's research activity has received the qualification ''Excellent'' in the Program 'Plan Profarma' (Program for Fostering Scientific Research, Technological Development and Innovation ...read more
PENSA PHARMA HAS BEEN AWARDED A PRIZE FOR ITS BEST DEVELOPMENT AND COMMERCIALIZATION OF GENERIC MEDICINES
Pensa Pharma (PENSA), a company of the ESTEVE Group specialized in generic medicines, has been awarded a prize at the II edition of La Razón Comunidad Valenciana Awards. Specifically, PENSA has receiv...read more
ESTEVE APPOINTS THOMAS B. RIISAGER AS CHIEF CORPORATE STRATEGY & BUSINESS DEVELOPMENT OFFICER
ESTEVE has announced today the appointment of Thomas B Riisager as Chief Corporate Strategy & Business Development Officer, to be heading Corporate Strategy & Business Development for the pharmaceutic...read more